These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10418989)

  • 1. Suppression of gene expression by tethering KRAB domain to promoter of ER target genes.
    Ma ZQ; Tsai MJ; Tsai SY
    J Steroid Biochem Mol Biol; 1999; 69(1-6):155-63. PubMed ID: 10418989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of estrogen receptor ligand and estrogen response element sequence on interaction with chicken ovalbumin upstream promoter transcription factor (COUP-TF).
    Klinge CM
    J Steroid Biochem Mol Biol; 1999 Nov; 71(1-2):1-19. PubMed ID: 10619353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.
    Zou A; Marschke KB; Arnold KE; Berger EM; Fitzgerald P; Mais DE; Allegretto EA
    Mol Endocrinol; 1999 Mar; 13(3):418-30. PubMed ID: 10076999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor-alpha 1 promoter via a novel sequence.
    Elgort MG; Zou A; Marschke KB; Allegretto EA
    Mol Endocrinol; 1996 May; 10(5):477-87. PubMed ID: 8732679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity.
    Fan JD; Wagner BL; McDonnell DP
    Mol Endocrinol; 1996 Dec; 10(12):1605-16. PubMed ID: 8961270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene.
    Ayyanathan K; Fredericks WJ; Berking C; Herlyn M; Balakrishnan C; Gunther E; Rauscher FJ
    Cancer Res; 2000 Oct; 60(20):5803-14. PubMed ID: 11059777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor-KRAB chimeras are potent ligand-dependent repressors of estrogen-regulated gene expression.
    de Haan G; Chusacultanachai S; Mao C; Katzenellenbogen BS; Shapiro DJ
    J Biol Chem; 2000 May; 275(18):13493-501. PubMed ID: 10788463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
    Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
    J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen-induced and TAFII30-mediated gene repression by direct recruitment of the estrogen receptor and co-repressors to the core promoter and its reversal by tamoxifen.
    Hao H; d'Alincourt-Salazar M; Kelley KM; Shatnawi A; Mukherjee S; Shah YM; Ratnam M
    Oncogene; 2007 Dec; 26(57):7872-84. PubMed ID: 17599049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor.
    Zhang X; Jeyakumar M; Petukhov S; Bagchi MK
    Mol Endocrinol; 1998 Apr; 12(4):513-24. PubMed ID: 9544987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A fusion protein of the estrogen receptor (ER) and nuclear receptor corepressor (NCoR) strongly inhibits estrogen-dependent responses in breast cancer cells.
    Chien PY; Ito M; Park Y; Tagami T; Gehm BD; Jameson JL
    Mol Endocrinol; 1999 Dec; 13(12):2122-36. PubMed ID: 10598586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different estrogen receptor structural domains are required for estrogen- and tamoxifen-dependent anti-proliferative activity in human mammary epithelial cells expressing an exogenous estrogen receptor.
    Zajchowski DA; Webster L; Humm R; White FA; Simmons SJ; Bartholdi M
    J Steroid Biochem Mol Biol; 1997 Aug; 62(5-6):373-83. PubMed ID: 9449240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor.
    Morrison AJ; Herrera RE; Heinsohn EC; Schiff R; Osborne CK
    Mol Endocrinol; 2003 Aug; 17(8):1543-54. PubMed ID: 12730327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
    Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
    Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen agonism and estrogen antagonism of c-fos gene promoter activity through non-consensus-responsive elements in MC3T3-E1 osteoblasts.
    Ishibashi O; Yamagishi T; Hanada K; Kawashima H
    Biochem Biophys Res Commun; 2001 Dec; 289(3):705-11. PubMed ID: 11726205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.
    Keeton EK; Brown M
    Mol Endocrinol; 2005 Jun; 19(6):1543-54. PubMed ID: 15802375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptors: selective ligands, partners, and distinctive pharmacology.
    Katzenellenbogen BS; Montano MM; Ediger TR; Sun J; Ekena K; Lazennec G; Martini PG; McInerney EM; Delage-Mourroux R; Weis K; Katzenellenbogen JA
    Recent Prog Horm Res; 2000; 55():163-93; discussion 194-5. PubMed ID: 11036937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT.
    Jackson TA; Richer JK; Bain DL; Takimoto GS; Tung L; Horwitz KB
    Mol Endocrinol; 1997 Jun; 11(6):693-705. PubMed ID: 9171233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
    Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of breast cancer cells on the basis of a functional assay for estrogen receptor.
    Biswas DK; Averboukh L; Sheng S; Martin K; Ewaniuk DS; Jawde TF; Wang F; Pardee AB
    Mol Med; 1998 Jul; 4(7):454-67. PubMed ID: 9713824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.